why is compound semaglutide not fda approved for weight loss | Blog The FDA's Decision to Ban

NICE guidance (NG28) on type 2 diabetes management does not include the combination of GLP-1 receptor agonists and DPP-4 inhibitors in its recommended treatment algorithms

Retatrutide supplied by our platform is exclusively intended for research and laboratory use

Enrolling in copay assistance or savings programs with the manufacturer

For example, pharmacists were seeing Saxenda, Wegovy, and Zepbound being prescribed for patients who did not have a body mass index (BMI) of 30 kg/m2 or a BMI of 27 kg/m2 with at least one weight associated comorbidity

At that time, 71% of the dulaglutide 1.5-mg group had an HbA 1c below 7.0%, as did 59% of patients on dulaglutide 0.75 mg and 49% on exenatide

J Transl Med 24 , 532 (2026)